Lexeo Therapeutics
Nasdaq LXEO · New York, NY
Works in Cardiovascular · Genetic & rare · Metabolic & endocrine · Neurology · Psychiatry
Lexeo Therapeutics is a clinical trial sponsor based in New York, NY, listed as Nasdaq LXEO. It has 7 active clinical trials with 169 planned participants, across 5 therapeutic areas. Since 2021 it has completed 1 trial and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq LXEO
Fundraising
Pipeline · 7 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Lexeo Therapeutics
Lexeo Therapeutics is lead sponsor of 7 active clinical trials on ClinicalTrials.gov, with 169 planned participants, in Cardiovascular, Genetic & rare, Metabolic & endocrine, Neurology and other areas. Since 2021 it has completed 1 trial and stopped 0 early.
Lexeo Therapeutics is based in New York, NY and is listed as Nasdaq LXEO. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Lexeo Therapeutics; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-09-02.
Approve Suite is not affiliated with Lexeo Therapeutics.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.